<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887587</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00020384</org_study_id>
    <nct_id>NCT01887587</nct_id>
  </id_info>
  <brief_title>Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia</brief_title>
  <official_title>Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ehab L Atallah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of vincristine, doxorubicin and dexamethasone (modified VXD) plus&#xD;
      MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma,&#xD;
      lymphoblastic lymphoma or mixed phenotype acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I study, escalating doses of MLN9708 will be combined with a fixed dose&#xD;
      modified VXD regimen. The study drug, MLN9708, will be administered on day 1, 8, and 15. If&#xD;
      the patient experiences a dose limiting toxicity (DLT) the dose of MLN9708 maybe reduced to&#xD;
      the next dose level on day 8 or day 15 in that patient. DLT would be any grade 3 or more&#xD;
      toxicity which is thought to be probably or definitely related to MLN9708. Three patients&#xD;
      will be treated per dose level unless DLT is observed. The starting dose of MLN9708 will be&#xD;
      2.3 mg orally on days 1, 8 and 15. If toxicity is seen at this level then dose may be reduced&#xD;
      to 1.5 mg (dose level -1) . If no DLT is seen in the first 3 patients, the dose will be&#xD;
      increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I&#xD;
      design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with&#xD;
      acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs&#xD;
      would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six&#xD;
      patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.&#xD;
      The maximum tolerated dose (MTD) will be the highest dose administered at which no more than&#xD;
      1 DLT was observed. All patients will be evaluated for hematopoetic stem cell&#xD;
      transplantation. If patients achieve complete response (CR) and are eligible for&#xD;
      hematopoietic stem cell transplantation (HSCT), they will proceed to HSCT. If they are not&#xD;
      eligible, no donor is identified or if HSCT will be delayed, and the patient has achieved&#xD;
      benefit, then treatment maybe repeated at the discretion of the investigator. A total of 9-18&#xD;
      patients will be enrolled on the study. The study duration would be about 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    SAE- risk of overall protocol treatment outweighs benefits&#xD;
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events.</measure>
    <time_frame>Baseline to 30 days post treatment; approximately 8 weeks</time_frame>
    <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal Dose of MLN9708</measure>
    <time_frame>8 Weeks</time_frame>
    <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Relapsed or Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed or Refractory Lymphoblastic Lymphoma</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone- 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.&#xD;
MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.&#xD;
For patients without central nervous system (CNS) involvement:&#xD;
Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg administered intrathecally on day 8&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Ixazomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Doxil</other_name>
    <other_name>hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexasone</other_name>
    <other_name>Solurex</other_name>
    <other_name>Baycadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Each patient must meet all of the following inclusion criteria to be enrolled in the study:&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          -  Male or female patients 18 years or older&#xD;
&#xD;
          -  Have relapsed B or T-precursor acute lymphocytic leukemia/lymphoma, lymphoblastic&#xD;
             lymphoma or mixed phenotype acute leukemia with increased bone marrow or peripheral&#xD;
             blood blasts by morphology with or without CNS involvement&#xD;
&#xD;
          -  Prior therapy: At least two prior treatment attempts to induce remission with no limit&#xD;
             on the number of prior treatment regimens.&#xD;
&#xD;
          -  Patients are eligible after allogeneic stem cell transplantation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Patients must meet the following clinical laboratory criteria:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1,000/cmm and platelets &gt; 75,000/cmm unless the&#xD;
                  cytopenias are secondary to disease&#xD;
&#xD;
          -  Life expectancy reasonably adequate for evaluating the treatment effect&#xD;
&#xD;
          -  Patients must be at least 2 weeks from major surgery, radiation therapy, participation&#xD;
             in other investigational trials and have recovered from clinically significant&#xD;
             toxicities of these prior treatments&#xD;
&#xD;
          -  Female patients who:&#xD;
&#xD;
               -  Are postmenopausal for at least 1 year before the screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 2 effective methods of&#xD;
                  contraception, at the same time, from the time of signing the informed consent&#xD;
                  form through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree&#xD;
             to one of the following:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria are not to be enrolled in the&#xD;
        study:&#xD;
&#xD;
          -  Patients who are Ph+ ALL who are naive to therapy with an approved tyrosine kinase&#xD;
             inhibitor.&#xD;
&#xD;
          -  Prior exposure to ≥350 mg/m2 of anthracycline (in doxorubicin equivalent dosing), or&#xD;
             left ventricular fractional shortening less than 50%.&#xD;
&#xD;
          -  Failure to have fully recovered (ie, ≤ Grade 2 toxicity) from the effects of prior&#xD;
             chemotherapy regardless of the interval since last treatment.&#xD;
&#xD;
          -  Major surgery within 14 days before enrollment.&#xD;
&#xD;
          -  Chemotherapy in the last 14 days. (Steroids or Intrathecal chemotherapy will be&#xD;
             allowed).&#xD;
&#xD;
          -  Systemic treatment, within 7 days before study enrollment, with strong inhibitors of&#xD;
             cytochrome P450 1A2 (CYP1A2) (e.g., fluvoxamine, enoxacin, ciprofloxacin), strong&#xD;
             inhibitors of cytochrome P4503A (CYP3A) (e.g., clarithromycin, telithromycin,&#xD;
             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A&#xD;
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),&#xD;
             or use of Ginkgo biloba or St. John's wort.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements. Patients receiving&#xD;
             intravenous antibiotics for infections that are under control may be included in this&#xD;
             study.&#xD;
&#xD;
          -  Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent.&#xD;
&#xD;
          -  Inability to swallow oral medication, inability or unwillingness to comply with the&#xD;
             drug administration requirements, or GI procedure that could interfere with the oral&#xD;
             absorption or tolerance of treatment.&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are&#xD;
             not excluded if they have undergone complete resection.&#xD;
&#xD;
          -  Patient has ≥ Grade 2 peripheral neuropathy.&#xD;
&#xD;
          -  Participation in clinical trials with other investigational agents not included in&#xD;
             this trial, within 14 days of the start of this trial and throughout the duration of&#xD;
             this trial.&#xD;
&#xD;
          -  Female patients who are breastfeeding or have a positive serum pregnancy test during&#xD;
             the screening period or a positive urine pregnancy test on Day 1 before first dose of&#xD;
             study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab L Atallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <results_first_submitted>August 13, 2019</results_first_submitted>
  <results_first_submitted_qc>December 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Ehab L Atallah</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01887587/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01887587/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone- 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.&#xD;
For patients without central nervous system (CNS) involvement:&#xD;
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone- 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.&#xD;
For patients without CNS involvement:&#xD;
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).&#xD;
MLN9708&#xD;
Vincristine&#xD;
Doxorubicin&#xD;
Dexamethasone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="25" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events.</title>
        <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
        <time_frame>Baseline to 30 days post treatment; approximately 8 weeks</time_frame>
        <population>At dose level one, 3 patients who were enrolled. The protocol was amended to remove PEGaspargase from the regimen. Two additional patients were enrolled on dose level one.</population>
        <group_list>
          <group group_id="O1">
            <title>(Modified VXLD) Plus MLN9708</title>
            <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone- 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.&#xD;
For patients without CNS involvement:&#xD;
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).&#xD;
MLN9708&#xD;
Vincristine&#xD;
Doxorubicin&#xD;
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events.</title>
          <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
          <population>At dose level one, 3 patients who were enrolled. The protocol was amended to remove PEGaspargase from the regimen. Two additional patients were enrolled on dose level one.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optimal Dose of MLN9708</title>
        <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
        <time_frame>8 Weeks</time_frame>
        <population>All five subjects received the same 2.3 mg oral dose of MLN9708.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified VXLD Plus MLN9708</title>
            <description>Vincristine -1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone - 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin - 60 mg/m2 on day 1 by IV bolus.&#xD;
MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Subsequent escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.&#xD;
For patients without CNS involvement:&#xD;
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day).</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Dose of MLN9708</title>
          <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
          <population>All five subjects received the same 2.3 mg oral dose of MLN9708.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks following last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22&#xD;
Dexamethasone- 10 mg/m2 orally or IV on days 1-14&#xD;
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.&#xD;
For patients without CNS involvement:&#xD;
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)&#xD;
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)&#xD;
For patients with CNS involvement:&#xD;
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).&#xD;
MLN9708&#xD;
Vincristine&#xD;
Doxorubicin&#xD;
Dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ehab Atallah, MD</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-805-8900</phone>
      <email>eatallah@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

